Table 2.
Characteristics of patients
| Characteristic | Total | Adherence(d) | p value | |
|---|---|---|---|---|
| Adherence | Non-adherence | |||
| Number of patients (%) | 119 | 87 (73.1 %) | 32 (26.9 %) | |
| Gender | ||||
| Male | 70 (58.8 %) | 53 (60.9 %) | 17 (53.1 %) | 0.4437 |
| Age | ||||
| Mean ± SD(a) | 45.7 ± 16.9 | 45.3 ± 16.9 | 46.7 ± 17.4 | 0.6923 |
| Median (Q1, Q3) | 46 (31.5, 58.8) | 44 (31, 58.3) | 48.5 (33.3, 60.8) | |
| Over 50 years | 47 (40.5 %) | 36 (41.9 %) | 11 (36.7 %) | 0.6178 |
| Follow-up time (year) | ||||
| Total (patient-years) | 469.2 | 364.3 | 104.9 | |
| Mean ± SD(a) | 3.9 ± 2.9 | 4.2 ± 2.9 | 3.3 ± 2.8 | 0.1463 |
| Median (Q1, Q3) | 3 (1.5, 6) | 3.8 (1.6, 6.3) | 2.1 (1.5, 5.2) | |
| CCI score (%)(b) | 0.6800 | |||
| 0 | 78 (65.5 %) | 57 (65.5 %) | 21 (65.6 %) | |
| 1 | 29 (24.4 %) | 20 (23 %) | 9 (28.2 %) | |
| 2 | 9 (7.6 %) | 8 (9.2 %) | 1 (3.1 %) | |
| 3 | 3 (2.5 %) | 2 (2.3 %) | 1 (3.1 %) | |
| Disease stages at imatinib initiating | 0.6728 | |||
| Chronic phase | 92 (77.3 %) | 68 (78.2 %) | 24 (75.0 %) | |
| Accelerated phase | 21 (17.6 %) | 14 (16.1 %) | 7 (21.9 %) | |
| Blast phase | 6 (5.1 %) | 5 (5.7 %) | 1 (3.1 %) | |
| Prior treatments | ||||
| Interferon | 37 (31.1 %) | 21 (24.1 %) | 16 (50.0 %) | 0.0069* |
| HSCT(c) | 2 (1.7 %) | 2 (2.3 %) | 0 | 0.3843 |
| Second-generation TKIs | 1 (0.8 %) | 1 (1.1 %) | 0 | 0.5425 |
| Hydroxyurea | 79 (66.4 %) | 55 (63.2 %) | 24 (75 %) | 0.2277 |
| Prior treatment-naïve patients | 30 (25.2 %) | 24 (28.6 %) | 6 (18.8 %) | 0.3147 |
| Time to initiate imatinib initiating (year) | ||||
| Mean ± SD(a) | 0.7 ± 1.7 | 0.6 ± 1.4 | 1.3 ± 2.5 | 0.0845 |
| Median (Q1, Q3) | 0.1 (0.01, 0.4) | 0.1 (0.01, 0.2) | 0.1 (0.01, 2.1) | |
| Imatinib-related side effects | ||||
| Grade II leukocytopenia | 22 (18.5 %) | 10 (11.5 %) | 12 (37.5 %) | 0.0012* |
| Grade II thrombocytopenia | 49 (41.2 %) | 29 (33.3 %) | 20 (62.5 %) | 0.0042* |
| Grade II hepatotoxicity | 11 (9.2 %) | 7 (8 %) | 4 (12.5 %) | 0.7540 |
(a) SD standard deviation. (b) CCI Charlson comorbidity index. (c) HSCT hematopoietic stem cell transplantation. (d)Adherence: patients whose imatinib medication possession ratio (MPR) ≥ 90 %; non-adherence: patients whose imatinib medication possession ratio (MPR) < 90 %